

Amendments to the Specification:

Please replace the paragraph beginning at page 6, line 28, with the following rewritten paragraph:

--~~Figure 1~~ Figures 1A and 1B present the nucleotide and amino acid sequence of factor X
(~~Seq. ID NO. 1 and 2~~) (SEQ ID NOS: 1 and 2).--

Please replace the paragraph beginning at page 7, line 3, with the following rewritten paragraph:

--Figure 4 shows a Western blot analysis after the in vitro activation of the factor X analog with factor ~~Xia~~XIa.--

Please replace the paragraph beginning at page 7, line 9, with the following rewritten paragraph:

--The present invention provides a Factor X analog with a modification in the region of amino-acid residues 226-235 with reference to the sequence shown in ~~Figure 1~~Figures 1A and 1B.--

Please replace the paragraph beginning at page 8, line 15, with the following rewritten paragraph:

-- To ensure optimum processing, in some cases, it may be necessary to ~~find a~~ modify the amino acid Ile235. Preferably, however, the NH₂-terminal amino acid isoleucine of the heavy chain should be maintained after the activation since this amino acid plays an important role in the formation of the substrate-binding pocket (Watzke et al.(1995), Molecular Basis of Thrombosis and Hemostasis, eds. Katherine High and Harold Roberts). Compared to the native factor X sequence, the factor X analogs according to the present invention are structurally different, in particular on the amino acid level, but their ability to be activated is comparable to the naturally occurring factor X and, after activation, factor Xa activity.

Please replace the paragraph beginning at page 8, line 24, with the following rewritten paragraph:

--The invention makes available factor X analogs which are modified in the activation peptide relative to the naturally occurring factor X sequence and which have a changed protease specificity. Amino acid ~~Modifications~~ modifications may take place in position Ile235 (R1), Arg234, Thr233 (R2), Leu 232 (R3), Asn231 (R4), Asn230 (R5), Asp229 (R6), Gly228 (R7), and Arg~~229~~227 (R8), while Arg234, however, preferably remains unchanged.--